


# Comparative efficacy and safety of interventions for treating head lice: a protocol for systematic review and network meta-analysis

Bill Stevenson,<sup>1</sup> Wubshet Tesfaye,<sup>1</sup> Julia Christenson,<sup>1</sup> Cynthia Mathew,<sup>1</sup> Solomon Abrha,<sup>1</sup> Gregory Peterson,<sup>1,2</sup> Indira Samarawickrema,<sup>1</sup> Jackson Thomas <sup>1</sup>

**To cite:** Stevenson B, Tesfaye W, Christenson J, et al. Comparative efficacy and safety of interventions for treating head lice: a protocol for systematic review and network meta-analysis. *BMJ Paediatrics Open* 2021;**5**:e001129. doi:10.1136/bmjpo-2021-001129

► Additional online supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjpo-2021-001129>).

Received 15 April 2021  
Revised 22 April 2021  
Accepted 24 April 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>Faculty of Health, University of Canberra, Canberra, Australian Capital Territory, Australia  
<sup>2</sup>Pharmacy, University of Tasmania, Hobart, Tasmania, Australia

## Correspondence to

Dr Jackson Thomas; Jackson.Thomas@canberra.edu.au

## ABSTRACT

**Background** Head lice infestation is a major public health problem around the globe. Its treatment is challenging due to product failures resulting from rapidly emerging resistance to existing treatments, incorrect treatment applications and misdiagnosis. Various head lice treatments with different mechanism of action have been developed and explored over the years, with limited report on systematic assessments of their efficacy and safety. This work aims to present a robust evidence summarising the interventions used in head lice.

**Method** This is a systematic review and network meta-analysis which will be reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement for network meta-analyses. Selected databases, including PubMed, Embase, MEDLINE, Web of Science, CINAHL and Cochrane Central Register of Controlled Trials will be systematically searched for randomised controlled trials exploring head lice treatments. Searches will be limited to trials published in English from database inception till 2021. Grey literature will be identified through Open Grey, AHRQ, Grey Literature Report, Grey Matters, ClinicalTrials.gov, WHO International Clinical Trials Registry and International Standard Randomised Controlled Trials Number registry. Additional studies will be sought from reference lists of included studies. Study screening, selection, data extraction and assessment of methodological quality will be undertaken by two independent reviewers, with disagreements resolved via a third reviewer. The primary outcome measure is the relative risk of cure at 7 and 14 days postinitial treatment. Secondary outcome measures may include adverse drug events, ovicidal activity, treatment compliance and acceptability, and reinfestation. Information from direct and indirect evidence will be used to generate the effect sizes (relative risk) to compare the efficacy and safety of individual head lice treatments against a common comparator (placebo and/or permethrin). Risk of bias assessment will be undertaken by two independent reviewers using the Cochrane Risk of Bias tool and the certainty of evidence assessed using the Grading of Recommendations, Assessment, Development and Evaluations guideline for network

## What is already known on this topic?

- Head lice infestation is a significant public health problem affecting people irrespective of socioeconomic backgrounds.
- Several interventions including insecticides, occlusive agents and physical methods are available for head lice treatment.

## What this study hopes to add?

- Despite the presence of several interventions, there is no reliable comparative data on the relative efficacy and safety of the interventions.
- It is not well established whether the dose, formulation, number of treatments and duration of head lice interventions have any meaningful impact on treatment outcomes.
- There is no strong evidence on the ovicidal activity of existing treatments.

meta-analysis. All quantitative analyses will be conducted using STATA V.16.

**Discussion** The evidence generated from this systematic review and meta-analysis is intended for use in evidence-driven treatment of head lice infestations and will be instrumental in informing health professionals, public health practitioners and policy-makers.

**PROSPERO registration number** CRD42017073375.

## BACKGROUND

Head lice infestation (*Pediculus humanus capitis*) is a global public health issue that affects people of all socioeconomic backgrounds.<sup>1–3</sup> Although there is a lack of reliable data, the prevalence estimates of head lice infestations in school-aged children range from 5% in Europe to 33% in Central and South America.<sup>4</sup> Head lice infestations affect people regardless of ethnicity and age, although it is more common among children


**Table 1** A partial summary of treatments for head lice, adapted from Diamantis *et al*<sup>48</sup>

Agents	Mechanism of action	Common adverse effects; limitations
Pyrethrins	Sodium channel blocker, neurotoxic and leads to paralysis and death of the parasite	Local irritation, allergy
Malathion	Acetylcholinesterase inhibitor, leads to spastic paralysis and death.	Scalp dryness, local irritation, dandruff, chemical conjunctivitis if contact with eyes occurs
Permethrin	Synthetic drug similar to pyrethrins. Sodium channel blocker as above.	Local irritation, allergy
Conditioners and Lathers	Physically blocks movement of lice, allowing easier physical removal	Time consuming, limited efficacy highly dependent on correct methodology, repeat treatments are often required
Fine combs	Used for manual physical removal, often with conditioners.	Limited efficacy alone, repeat treatments are often required

aged 7–14 years, females and vulnerable populations dwelling in crowded environments.<sup>1 5 6</sup> Head lice infestation causes parental anxiety and acts as a source of economic loss through missed school days and caregiver time off work<sup>7</sup>—the annual cost in the US alone was estimated at more than US\$1 billion.<sup>8</sup>

Head lice causes considerable discomfort, and intensive itching that could lead to poor sleep and excoriation—although uncommon, skin breaches superinfected with resistant pathogenic bacteria can lead to secondary skin infections and lymphadenopathies.<sup>9 10</sup> Also, affected children and their parents often suffer from social stigma, embarrassment and low self-esteem,<sup>11 12</sup> and some jurisdictions prevent children with head lice from attending schools altogether, resulting in school absenteeism and economic loss through caregiver absence from work.<sup>13 14</sup> Consequently, governments dedicate a relatively large amount of resources to develop new products and to design strategies for the control and prevention head lice.

There are a range of interventions available for the management of head lice (table 1).<sup>15</sup> The main stay of therapy has been largely dependent on insecticidal-based approaches for several decades. However, the accumulating evidence with resistance to frontline insecticidal treatments like pyrethrins, permethrin and malathion has led to a growing incentive to develop newer and more effective treatments to treat the condition safely.<sup>1</sup> Over the past couple of decades, alternative candidates have been introduced into the market, including ivermectin,<sup>16–18</sup> occlusive agents (eg, benzyl alcohol, isopropyl myristate and dimethicone)<sup>19–21</sup> and herbal products<sup>22</sup> and essential oils.<sup>22–25</sup> While drugs with novel mode of action may potentially tackle the rapidly growing issue of resistance, in the absence of strong comparative evidence, the relative efficacy and safety of the newer agents and how they fare with insecticidal treatments remain unclear.

In addition to the variety of treatments, the significantly varied trial formats, and conflicting reviews from preceding decades make treatment choice in head lice management difficult.<sup>26 27</sup> This has, in turn, caused a degree of ambiguity in terms of the relative efficacy

and safety of currently existing head lice treatments.<sup>26</sup> Further, owing to the increasing resistance to conventional treatments, there is a high incidence of treatment failure.<sup>28</sup> Low effectiveness of the insecticidal products and the unproven nature of herbal products have led to parents resorting to dangerous alternatives, such as kerosene or veterinary flea products, in a desperate attempt to cure recalcitrant head lice infestations. Several studies<sup>29–31</sup> reported safety issues with many commonly used head lice treatments ranging from local itchiness<sup>30</sup> to severe neurological conditions.<sup>31</sup> While there is some literature on the subject,<sup>32</sup> to our knowledge, there is lack of robust comparative evidence on the efficacy and safety of current treatments.<sup>11</sup> Therefore, there is a critical need to evaluate the effectiveness and the safety profile of current head lice treatments to make evidence-informed recommendations for health practitioners and wider community and thereby minimise the burden of head lice.

Between 1990 and 2001, only two major systematic reviews were conducted examining the effect of head lice treatments, both of these studies had substantial methodological limitations and reported inconclusive findings.<sup>26</sup> Vander Stichele *et al*<sup>33</sup> concluded that only permethrin had enough evidence in terms of efficacy to justify its use in head lice treatment. In contrast, the Cochrane review performed by Dodd<sup>34</sup> (published in 1999, and then revised in 2001) concluded that permethrin, malathion and pyrethrins were all effective treatments for head lice, although this conclusion relied on only three clinical trials that met their inclusion criteria. In 2006, the review by Dodd was withdrawn pending major substantive update—an updated study protocol that has since been, in turn, withdrawn in 2018.<sup>34</sup> There is a 2019 systematic review that compared occlusive and neurotoxic head lice treatments as a group but not as individual treatments.<sup>35</sup> It has been many years since a comprehensive systematic review and meta-analysis has been performed comparing individual head lice treatments.<sup>36</sup> With Dodd review withdrawn and the review by Vander Stichele *et al* 25 years old, recent evidence on head lice treatment is clearly wanting.<sup>33</sup>

This systematic review and network meta-analysis seeks to bridge this gap and aims to generate conclusive evidence about the efficacy and safety of head lice interventions, with a view to inform clinicians, policy-makers and the public to guide them in their efforts to improve the quality of head lice treatment in the community.

## METHODS

This study protocol is prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols (PRISMA)<sup>37</sup> and has been registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42019132524).

### Patient and public involvement

This protocol was designed without patient or public involvement.

### Search strategy, keywords

Preliminary searches of the literature will be conducted to identify the keywords, which will be integrated and listed to undertake a more extensive search. These will be combined with Boolean operators and medical subject headings to formulate a refined search method. To identify the keywords regarding head lice interventions, the key words ‘pediculos\*’, ‘pediculus humanus capitis’, ‘head lice’, ‘clinical trials’, ‘pediculicide\*’, ‘insecticide\*’, ‘shampoo’, ‘conditioner’ ‘randomised control trials’, ‘controlled treatment studies’, ‘disease management’, ‘interventions’, ‘permethrin’, ‘ivermectin’, ‘malathion’, ‘pyrethrins’, ‘human’, ‘phytotherapy’, ‘essential oil\*’, ‘drug therapy’ OR clinical OR routine OR ‘pharmaceutical preparations’ OR ‘treatment’ OR ‘intervention’ OR ‘therapy’ OR ‘medicine’ OR ‘management’ will be used. Clinical trials published till 2021 will be considered for inclusion. Both completed clinical trials and trials in progress will be considered. The search strategy will be developed based on the instructions in the Cochrane handbook for systematic reviews of interventions<sup>38</sup> and will be specific for each database. A detailed search strategy for PubMed, Embase via Scopus and Web of Science is shown in online supplemental appendix 1. The results will be presented in accordance with the PRISMA flow chart.

### Information databases

Electronic databases, including PubMed, Medline, the National Institute of Health and National Library of Medicine, SCOPUS, the Excerpt Medica Database (EMBASE), JURN and Google Scholar, will be searched for studies, along with the US clinical trials database (<https://clinicaltrials.gov/>), the Australia New Zealand Clinical Trial Registry <http://www.anzctr.org.au/>), the International Standard Randomised Controlled Trials Number (<https://www.isrctn.com/>) and the WHO’s International Clinical Trials Registry Platform (<https://www.who.int/ictrp/en/>). In addition, grey literature will be explored

via Informit, the OaIster database and the WHO. Further, the references of the included articles will also be thoroughly screened for relevant articles potentially missed during the main search.

### Types of studies to be included

Only primary randomised controlled trials (RCTs) that are published from inception of targeted databases until 2021 will be included based on the following criteria: participants of any age with live head lice or lice and eggs (not eggs alone) before enrolment studies with either placebo or active comparator group; and reported the outcomes of interest (pediculicidal and ovicidal activities).

### Participants/population

The review will consider studies that include participants of any age, gender or country of origin. Exclusion criteria include participants with other similar lice (such as *pediculus humanus* or ‘body lice’) and participants with inactive infections (characterised by no live adult or nymph lice and eggs >2 cm away from the scalp, if present).

### Intervention(s), exposure(s)

Any RCT investigating treatment for head lice will be included, regardless of the nature of the intervention. Such treatments may include insecticides, suffocation products, essential oils, desiccants, deterrents or pediculicides. As such, any intervention designed with the intent of reducing or curing an extant head lice infection will be considered in this review. Exceptions include treatments exclusively designed for ovicidal effects.

### Comparator(s)/control

Dependent on each trial, any comparator may be used. This may be between active therapeutic agents or between an active agent and a placebo.

### Outcome(s)

The main outcome is cure from an active infestation measured as proportion of participants being completely free from head lice after 7 days postlast treatment or within 14 days postfirst treatment. If a trial evaluated outcomes in days other than 7 or 14 days, this will be assigned to the standard time frame where appropriate (eg; an outcome assessed on days 6, 8, 9 or 10 will be assigned to day 7, while outcomes assessed on days 11–21 would be assigned as day 14). Secondary outcomes that will be considered in this review are ovicidal activity of drugs, adverse events, treatment compliance and acceptability, and reinfestation, whenever reported.

### Selection of studies

The retrieved citations will be transferred to Covidence<sup>39</sup> for screening, data extraction and risk of bias (RoB) assessment. Full texts of potentially relevant studies that pass initial screening will be examined for eligibility. Where possible, reviewers will attempt to contact primary authors via email when eligibility for inclusion is not

clear. Two independent reviewers will perform eligibility assessment, data extraction, and RoB assessment using the Covidence electronic platform. Any disagreements will be resolved by a third reviewer. Reasons for excluding studies/trials will be recorded.

### Data extraction

This systematic review will be reported in accordance with the recommendations of the PRISMA statement for network meta-analyses.<sup>40</sup> Two review authors will extract the data and check for discrepancies at each level (title, abstract and full text) using the inclusion and exclusion criteria. We will specifically extract the following data:

- ▶ General information: author, journal, year(s) the study took place, year of publication, country, sample size, sociodemographic characteristics of study participants; attrition and their characteristics.
- ▶ Study methodology: study design, inclusion/exclusion criteria, sample size.
- ▶ Details of intervention: dose, formulation, frequency and mode of application, duration of administration.
- ▶ Comparators: details of the comparator group—placebo, no treatment, control intervention of non-pharmacological nature or other medicine.
- ▶ Outcomes: clinical cure following the study intervention, secondary outcomes and results (including effect estimates; adverse effects, acceptability).
- ▶ Study limitations.
- ▶ User satisfaction/preference of studied treatments.

Where applicable, data extracted will also include: other secondary outcomes reported by the studies and not listed in this review, reasons for patient removal from the trial, major advantages or disadvantages identified in the trial and the method by which the primary outcome was measured (ie, how was the presence or absence of adult lice determined). Data will be tabulated and sorted by treatment for further analysis. If the primary outcome data are missing, the authors of relevant studies will be contacted (if possible) to supply missing information. If the data cannot be obtained, the study will be excluded.

### Strategy for data synthesis

Data will be collected by at least two reviewers independently and manually extracted from the selected papers. Discrepancy and disagreement will be discussed between reviewers when they occur until a consensus is reached. Key values will then be entered in a spreadsheet used by all reviewers. Once information has been extracted, it will be synthesised via a narrative approach and interpreted accordingly. Where possible, data will be tabulated for ease of access and readability.

A network meta-analysis will be performed based on the intention to treat population using a multivariate meta-analysis with consistency model,<sup>41</sup> with restricted maximum likelihood (REML) estimation applied to calculate the pooled RRs across studies, with the findings presented alongside the narrative interpretation of the data. This REML model is preferred given it is unlikely

to underestimate the variance like maximum likelihood estimation does. In terms of assessing between-study variations, the analysis assumes an exchangeable covariance structure at 0.5. Information from direct and indirect evidence will be used to generate the effect sizes (relative risk) for each treatment against a common comparator (placebo or permethrin). The efficacy and safety of the different head lice treatments will be ranked using the surface under the cumulative ranking curve, which shows the percentage efficacy and safety of individual treatment against a hypothetically ideal treatment. Interventions will be considered at the level of an individual drug and outcome data for multiple doses or dosage formulations of a given intervention will be merged under a single treatment node. The agreement between estimates from direct and indirect evidence will be assessed using a design-by-treatment interaction model.<sup>42</sup> The hypothesis of inconsistency will be assessed by globally testing all inconsistency parameters using a global Wald test statistic,<sup>43</sup> while publication bias will be assessed using comparison-adjusted funnel plots.<sup>44</sup>

All quantitative analyses will be conducted using STATA V.16 (StataCorp) and a two-sided  $p < 0.05$  will be used to show statistical significance.

### RoB assessment and grading of evidence

The Cochrane RoB 2 (RoB-2)<sup>45</sup> tool will be used to assess RoB in included studies, focusing on biases related to five key domains: randomisation process, deviations from intended interventions, missing outcome data, outcome measures and selection of the reported result. Each domain will receive a judgement on the RoB (high, low or some concerns) and an overall RoB will be assigned based on the judgements from the five domains. Each of two reviewers will independently apply the tool to each paper to determine its bias category, then confer with other reviewer. Any disagreements between the reviewers will be resolved by discussion with a third reviewer.

We will use the Grading of Recommendations Assessment, Development and Evaluation approach for network meta-analysis<sup>46 47</sup> to report the quality of evidence on the efficacy and acceptability of different interventions to be included in the systematic review. The rate of quality for direct and indirect evidence will be performed separately, which will then be used to rate the quality of the network meta-analysis. The quality of evidence associated with direct comparisons will be assessed based on five key domains (methodology quality, the directness of evidence, heterogeneity, the precision of effect estimates and risk of publication bias). Given only randomised trials will be included, all the studies in the quality assessment will start from high and then be downrated for the reasons mentioned. In the case of the indirect evidence, factors like intransitivity (based on narrative comparisons of study characteristics) and network coherence (based on differences in direct and indirect effect estimates) will be used to assess the quality of evidence. Finally, the quality of evidence for the network will consider the

direct and indirect evidence for the inventions and will be reported as high, moderate, low and very low.

## DISCUSSION

This systematic review and network meta-analysis of head lice treatments is a comprehensive work aiming to provide a strong evidence base to understand the relative efficacy and safety of existing head lice interventions. By considering and comparing the evidence on important attributes of investigated drugs, including efficacy, safety and tolerability, ease of application, and cost, the reviewers will attempt to make clinical recommendations for head lice treatment. Furthermore, this work is anticipated to highlight the gaps in existing research on head lice treatments and illuminate the way forward. The last major systematic review in this area was published nearly two decades ago only to be withdrawn soon after. This work will provide consolidated, decisive evidence to inform clinicians on the best choice of intervention to treat a head lice infestation. However, due to the inclusion of RCTs only, we may miss on important rare adverse events associated with the treatments, which would have been observed in large-scale cohort studies.

**Twitter** Wubshet Tesfaye @WubeHT

**Contributors** BS, WT and JT conceived the idea. BS, WT, SA, CM, IS and GP contributed to the drafting and editing of the manuscript. All authors agreed on the final version of the manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** Ethics approval will not be required given the published works are available in the public domain. The findings from this systematic review will be communicated to the appropriate audience through conference abstract/s and a peer-reviewed journal publication.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID ID

Jackson Thomas <http://orcid.org/0000-0002-0699-788X>

## REFERENCES

- 1 Falagas ME, Matthaiou DK, Rafailidis PI, et al. Worldwide prevalence of head lice. *Emerg Infect Dis* 2008;14:1493–4.
- 2 Burgess IF. Head lice. *BMJ Clin Evid* 2011;2011. [Epub ahead of print: 16 May 2011].
- 3 Burgess IF, Silverston P. Head lice. *BMJ Clin Evid* 2015;2015. [Epub ahead of print: 14 Jan 2015].
- 4 Hatam-Nahavandi K, Ahmadpour E, Pashazadeh F, et al. Pediculosis capitis among school-age students worldwide as an emerging public health concern: a systematic review and meta-analysis of past five decades. *Parasitol Res* 2020;119:3125–43.
- 5 Speare R, Buettner PG. Head lice in pupils of a primary school in Australia and implications for control. *Int J Dermatol* 1999;38:285–90.
- 6 Monheit BM, Norris MM. Is combing the answer to headlice? *J Sch Health* 1986;56:158.
- 7 Frankowski BL, Bocchini JA, Council on School Health and Committee on Infectious Diseases. Head lice. *Pediatrics* 2010;126:392–403.
- 8 McCormack PL. Spinosad: in pediculosis capitis. *Am J Clin Dermatol* 2011;12:349–53.
- 9 Mumcuoglu KY, Klaus S, Kafka D, et al. Clinical observations related to head lice infestation. *J Am Acad Dermatol* 1991;25:248–51.
- 10 Roberts RJ. Head lice. *N Engl J Med Overseas Ed* 2002;346:1645–50.
- 11 Hurst SK, Dotson JAW, Butterfield P, et al. Stigma resulting from head lice infestation: a concept analysis and implications for public health. *Nurs Forum* 2020;55:252–8.
- 12 Parison JC, Speare R, Canyon DV. Head lice: the feelings people have. *Int J Dermatol* 2013;52:169–71.
- 13 Frankowski BL, Bocchini JA, CoS H, Council on School Health and Committee on Infectious Diseases. Head lice. *Pediatrics* 2010;126:392–403.
- 14 Gordon SC. Shared vulnerability: a theory of caring for children with persistent head lice. *J Sch Nurs* 2007;23:283–92.
- 15 Moosazadeh M, Afshari M, Keianian H, et al. Prevalence of head lice infestation and its associated factors among primary school students in Iran: a systematic review and meta-analysis. *Osong Public Health Res Perspect* 2015;6:346–56.
- 16 Chosidow O, Giraudeau B, Cottrell J, et al. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. *N Engl J Med* 2010;362:896–905.
- 17 Meinking TL, Mertz-Rivera K, Villar ME, et al. Assessment of the safety and efficacy of three concentrations of topical ivermectin lotion as a treatment for head lice infestation. *Int J Dermatol* 2013;52:106–12.
- 18 Pariser DM, Meinking TL, Bell M, et al. Topical 0.5% ivermectin lotion for treatment of head lice. *N Engl J Med* 2012;367:1687–93.
- 19 Burgess IF, Brunton ER, Burgess NA. Single application of 4% dimeticone liquid gel versus two applications of 1% permethrin creme rinse for treatment of head louse infestation: a randomised controlled trial. *BMC Dermatol* 2013;13:5.
- 20 Burgess IF, Lee PN, Brown CM. Randomised, controlled, parallel group clinical trials to evaluate the efficacy of isopropyl myristate/cyclomethicone solution against head lice. *Pharmaceutical Journal* 2008;280:371–5.
- 21 Meinking TL, Villar ME, Vicaria M, et al. The clinical trials supporting benzyl alcohol lotion 5% (Ulesfia): a safe and effective topical treatment for head lice (pediculosis humanus capitis). *Pediatr Dermatol* 2010;27:19–24.
- 22 Williams CR, Webb CE, Orre S, et al. Can kunzea oil (Kunzea ambigua) control head lice (Pediculus humanus capitis)? *Parasitology Open* 2016;2:e3.
- 23 Di Campli E, Di Bartolomeo S, Delli Pizzi P, et al. Activity of tea tree oil and nerolidol alone or in combination against *Pediculus capitis* (head lice) and its eggs. *Parasitol Res* 2012;111:1985–92.
- 24 Greive KA, Lui AH, Barnes TM, et al. Safety and efficacy of a non-pesticide-based head lice treatment: results of a randomised comparative trial in children. *Australas J Dermatol* 2012;53:255–63.
- 25 Grieve K, Altman P, Rowe S, et al. A randomised, double-blind, comparative efficacy trial of three head lice treatment options: malathion, pyrethrins with piperonyl butoxide and MOOV head lice solution. *Aust Pharmacist* 2007;26:738–43.
- 26 Lapeere H, Vander Stichele RH, Naeyaert J-M. Evidence in the treatment of head lice: drowning in a swamp of reviews. *Clin Infect Dis* 2003;37:1580–2.
- 27 Sweileh WM. Global output of research on epidermal parasitic skin diseases from 1967 to 2017. *Infect Dis Poverty* 2018;7:74.
- 28 Downs AM, Stafford KA, Harvey I, et al. Evidence for double resistance to permethrin and malathion in head lice. *Br J Dermatol* 1999;141:508–11.
- 29 Clore ER, Longyear LA. A comparative study of seven pediculicides and their packaged nit removal combs. *J Pediatr Health Care* 1993;7:55–60.
- 30 Shuster J. Too much vitamin A lindane-induced CNS effects. *Hosp Pharm* 1996;31.



- 31 Hammond K, Leikin JB. Topical pyrethrin toxicity leading to acute-onset stuttering in a toddler. *Am J Ther* 2008;15:323–4.
- 32 Burkhart CG. Relationship of treatment-resistant head lice to the safety and efficacy of pediculicides. *Mayo Clin Proc* 2004;79:661–6.
- 33 Vander Stichele RH, Dezeure EM, Bogaert MG. Systematic review of clinical efficacy of topical treatments for head lice. *BMJ* 1995;311:604–8.
- 34 Dodd CS. Interventions for treating headlice. *Cochrane Database Syst Rev* 2001;2:CD001165.
- 35 Flores-Genuino RNS, Gnilo CMS, Dofitas BL. Occlusive versus neurotoxic agents for topical treatment of head lice infestation: a systematic review and meta-analysis. *Pediatr Dermatol* 2020;37:86–92.
- 36 Do-Pham G, Le Cleach L, Giraudeau B, et al. Designing randomized-controlled trials to improve head-lice treatment: systematic review using a vignette-based method. *J Invest Dermatol* 2014;134:628–34.
- 37 Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
- 38 Higgins J, Thomas J, Cochrane Community. Cochrane Handbook for systematic reviews of interventions, 2019. Available: <https://training.cochrane.org/handbook/current>
- 39 Covidence. Cochrane community, 2020. Available: <https://www.covidence.org/reviewers> [Accessed 23 Jun 2020].
- 40 Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015;162:777–84.
- 41 White IR. Multivariate Random-effects meta-analysis. *Stata J* 2009;9:40–56.
- 42 Higgins JPT, Jackson D, Barrett JK, et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. *Res Synth Methods* 2012;3:98–110.
- 43 White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. *Res Synth Methods* 2012;3:111–25.
- 44 Chaimani A, Higgins JPT, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. *PLoS One* 2013;8:e76654.
- 45 Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366:l4898.
- 46 Puhan MA, Schünemann HJ, Murad MH, et al. A GRADE Working group approach for rating the quality of treatment effect estimates from network meta-analysis. *BMJ* 2014;349:g5630.
- 47 Brignardello-Petersen R, Florez ID, Izcovich A, et al. GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. *BMJ* 2020;371:m3900.
- 48 Diamantis SA, Morrell DS, Burkhart CN. Treatment of head lice. *Dermatol Ther* 2009;22:273–8.

## APPENDIX 1: Search strategies

<b>PubMed</b>	
<b>#1</b>	"head lice" OR headlice OR pediculus [Mesh] OR pediculosis OR "head louse" OR "lice infestations/therapy" [Mesh]
<b>#2</b>	treatment OR therapy OR intervention OR therapeutics [Mesh] OR pediculid* OR insectid* OR shampoo OR crème rinse OR lotion OR mousse OR therapeutics OR ivermectin OR malathion OR permethrin OR dimeticone OR lindane OR crotamiton OR spinosad OR bioallethrin OR phenothrin OR piperonyl butoxide OR d-phenothrin OR carbaryl OR pyrethrin OR DDT OR benzyl alcohol OR benzyl benzoate OR isopropyl myristate OR clophenothane OR isopropyl alcohol OR stearyl alcohol OR albendazole OR thiabendazole OR levamisole OR diethylcarbamazine OR cotrimoxazole OR co-trimoxazole OR coconut OR anise OR Ylang-ylang OR mayonnaise OR petroleum jelly OR tub margarine OR herbal oil OR essential oil OR vinegar OR melted butter OR neem seed OR azadirachtin OR grapefruit OR melaleuca OR tee tree OR lavender OR natural product OR eucalyptus OR quassia OR paw OR thymol OR electr* OR bug OR bust* OR formic acid OR air OR shaving OR bald
<b>#3</b>	#1 AND #2
<b>Embase (via Scopus)</b>	
<b>#1</b>	pediculosis AND [mtree] OR pediculus AND [mtree] OR head AND louse OR head AND lice OR headlice OR pediculus OR pediculosis
<b>#2</b>	treatment OR therapy OR intervention OR pediculid* OR insectid* OR shampoo OR "crème rinse" OR lotion OR mousse OR therapeutics OR ivermectin OR malathion OR permethrin OR dimeticone OR lindane OR crotamiton OR spinosad OR bioallethrin OR phenothrin OR "piperonyl butoxide" OR d-phenothrin OR carbaryl OR pyrethrin OR ddt OR "benzyl alcohol" OR "benzyl benzoate" OR "isopropyl myristate" OR clophenothane OR "isopropyl alcohol" OR "stearyl alcohol" OR "albendazole" OR "thiabendazole" OR levamisole OR diethylcarbamazine OR cotrimoxazole OR co-trimoxazole OR coconut OR anise OR ylang-ylang OR mayonnaise OR "petroleum jelly" OR "tub margarine" OR "herbal oil" OR vinegar OR "melted butter" OR "neem seed" OR azadirachtin OR grapefruit OR melaleuca OR "tee tree" OR lavender OR "natural product" OR eucalyptus OR quassia OR paw OR thymol OR electr* OR bug OR bust* OR "formic acid" OR air OR shaving OR bald
<b>#3</b>	#1 AND #2
<b>Web of Science</b>	
<b>#1</b>	TS= ("head lice" OR headlice OR pediculus OR pediculosis OR "head louse" OR "lice infestations/therapy" ) Databases= WOS, CCC, KJD, MEDLINE, RSCI, SCIELO Timespan=All years Search language=Auto
<b>#2</b>	TS=(treatment OR therapy OR intervention OR pediculid* OR insectid* OR shampoo OR crème rinse OR lotion OR mousse OR therapeutics OR ivermectin OR malathion OR permethrin OR dimeticone OR lindane OR crotamiton OR spinosad OR bioallethrin OR phenothrin OR "piperonyl butoxide" OR d-phenothrin OR carbaryl OR pyrethrin OR DDT OR "benzyl alcohol" OR "benzyl benzoate" OR "isopropyl myristate" OR clophenothane OR "isopropyl alcohol" OR "stearyl alcohol" OR "albendazole" OR "thiabendazole" OR levamisole OR diethylcarbamazine OR cotrimoxazole OR co-trimoxazole OR coconut OR anise OR Ylang-ylang OR mayonnaise OR "petroleum jelly" OR "tub margarine" OR "herbal oil" OR vinegar OR "melted butter" OR "neem seed" OR azadirachtin OR grapefruit OR melaleuca OR "tee tree" OR lavender OR "natural product" OR eucalyptus OR quassia OR paw OR thymol OR electr* OR bug OR bust* OR "formic acid" OR air OR shaving OR bald ) Databases= WOS, CCC, KJD, MEDLINE, RSCI, SCIELO Timespan=All years Search language=Auto
<b>#3</b>	#1 AND #2

<b>Cochrane Library</b>	
<b>#1</b>	("head lice" OR headlice OR pediculus OR pediculosis OR "head louse" OR "lice infestations")
<b>#2</b>	treatment OR therapy OR intervention OR therapeutics OR pediculicid* OR insecticid* OR shampoo OR crème rinse OR lotion OR mousse OR therapeutics OR ivermectin OR malathion OR permethrin OR dimeticone OR lindane OR crotamiton OR spinosad OR bioallethrin OR phenothrin OR piperonyl butoxide OR d-phenothrin OR carbaryl OR pyrethrin OR DDT OR benzyl alcohol OR benzyl benzoate OR isopropyl myristate OR clophenothane OR isopropyl alcohol OR stearyl alcohol OR albendazole OR thiabendazole OR levamisole OR diethylcarbamazine OR cotrimoxazole OR co-trimoxazole OR coconut OR anise OR Ylang-ylang OR mayonnaise OR petroleum jelly OR tub margarine OR herbal oil OR essential oil OR vinegar OR melted butter OR neem seed OR azadirachtin OR grapefruit OR melaleuca OR tee tree OR lavender OR natural product OR eucalyptus OR quassia OR paw OR thymol OR electric OR bug OR buster OR formic acid OR air OR shaving OR bald in Title Abstract Keyword - with Publication Year from 2002 to 2020, with Cochrane Library publication date to May 2020, in Trials (Word variations have been searched)
<b>#3</b>	<b>#1 AND #2</b>
<b>CINAHL (via EBSCOhost)</b>	
<b>#1</b>	"head lice" OR headlice OR pediculus OR pediculosis OR "head louse" OR "lice infestations"
<b>#2</b>	treatment OR therapy OR intervention OR therapeutics OR pediculicid* OR insecticid* OR shampoo OR crème rinse OR lotion OR mousse OR therapeutics OR ivermectin OR malathion OR permethrin OR dimeticone OR lindane OR crotamiton OR spinosad OR bioallethrin OR phenothrin OR piperonyl butoxide OR d-phenothrin OR carbaryl OR pyrethrin OR DDT OR benzyl alcohol OR benzyl benzoate OR isopropyl myristate OR clophenothane OR isopropyl alcohol OR stearyl alcohol OR albendazole OR thiabendazole OR levamisole OR diethylcarbamazine OR cotrimoxazole OR co-trimoxazole OR coconut OR anise OR Ylang-ylang OR mayonnaise OR petroleum jelly OR tub margarine OR herbal oil OR essential oil OR vinegar OR melted butter OR neem seed OR azadirachtin OR grapefruit OR melaleuca OR tee tree OR lavender OR natural product OR eucalyptus OR quassia OR paw OR thymol OR electric OR bug OR buster OR formic acid OR air OR shaving OR bald
<b>#3</b>	<b>#1 AND #2 AND</b> [Limiter: Randomized Controlled Trials]
<b>MEDLINE (via EBSCOhost)</b>	
<b>#1</b>	("head lice" OR headlice OR pediculus OR pediculosis OR "head louse" OR "lice infestations")
<b>#2</b>	( treatment OR therapy OR intervention OR therapeutics OR pediculicid* OR insecticid* OR shampoo OR crème rinse OR lotion OR mousse OR therapeutics OR ivermectin OR malathion OR permethrin OR dimeticone OR lindane OR crotamiton OR spinosad OR bioallethrin OR phenothrin OR piperonyl butoxide OR d-phenothrin OR carbaryl OR pyrethrin OR DDT OR benzyl alcohol OR benzyl benzoate OR isopropyl myristate OR clophenothane OR isopropyl alcohol OR stearyl alcohol OR albendazole OR thiabendazole OR levamisole OR diethylcarbamazine OR cotrimoxazole OR co-trimoxazole OR coconut OR anise OR Ylang-ylang OR mayonnaise OR petroleum jelly OR tub margarine OR herbal oil OR essential oil OR vinegar OR melted butter OR neem seed OR azadirachtin OR grapefruit OR melaleuca OR tee tree OR lavender OR natural product OR eucalyptus OR quassia OR paw OR thymol OR electric OR bug OR buster OR formic acid OR air OR shaving OR bald )
<b>#3</b>	<b>#1 AND #2</b> [Limiters - Publication Type: Clinical Trial, Clinical Trial, Phase II, Clinical Trial, Phase III, Clinical Trial, Phase IV, Controlled Clinical Trial, Randomized Controlled Trial]



**APPENDIX 2: PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol\***

Section and topic	Item No	Checklist item	Self-Evaluation
<b>ADMINISTRATIVE INFORMATION</b>			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	Yes
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	Not applicable
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	<a href="#">CRD42019132524</a>
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	Provided
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	Provided
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	Not applicable
Support:			
Sources	5a	Indicate sources of financial or other support for the review	Not applicable
Sponsor	5b	Provide name for the review funder and/or sponsor	Not applicable
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	Not applicable
<b>INTRODUCTION</b>			
Rationale	6	Describe the rationale for the review in the context of what is already known	Provided
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	Yes
<b>METHODS</b>			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	Yes
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	Yes
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	Yes
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	Yes
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	Yes
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	Yes

Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	Yes
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	Yes
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	Yes
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	Yes
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$ , Kendall's $\tau$ )	Yes
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	Yes
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	Yes
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	Yes

**\* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.*